|

Alzheimer's Disease Clinical Trials in Chicago, IL

26 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Communication Bridge 3 StudyPhase 22 mi
Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)—2 mi
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's TypePhase 32 mi
Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's DementiaN/A2 mi
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesPhase 32 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)Phase 32 mi
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia—2 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)Phase 32 mi
Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog TrialN/A2 mi
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)Phase 22 mi
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePhase 32 mi
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePhase 32 mi
Feasibility of Using the Gatorade Sports Science Institute (GSSI) Labs App for Hydration Related Outcomes—2 mi
Longitudinal Early-onset Alzheimer's Disease Study Protocol—2 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseasePhase 32 mi
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantPhase 32 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Phase 39 mi
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's DiseasePhase 312 mi
OTC Hearing Aid and MCIN/A12 mi
Trial-Ready Cohort-Down Syndrome (TRC-DS)—14 mi
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPhase 2/314 mi
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPhase 2/314 mi
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)Phase 220 mi
ACP-204 in Adults With Alzheimer's Disease PsychosisPhase 2/335 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)Phase 335 mi
Late Onset Alzheimer's Disease—37 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.